WO2007056177A3 - T315a and f317i mutations of bcr-abl kinase domain - Google Patents

T315a and f317i mutations of bcr-abl kinase domain Download PDF

Info

Publication number
WO2007056177A3
WO2007056177A3 PCT/US2006/043019 US2006043019W WO2007056177A3 WO 2007056177 A3 WO2007056177 A3 WO 2007056177A3 US 2006043019 W US2006043019 W US 2006043019W WO 2007056177 A3 WO2007056177 A3 WO 2007056177A3
Authority
WO
WIPO (PCT)
Prior art keywords
abl kinase
bcr
mutations
kinase domain
kinase proteins
Prior art date
Application number
PCT/US2006/043019
Other languages
French (fr)
Other versions
WO2007056177A2 (en
WO2007056177A9 (en
Inventor
Charles L Sawyers
Michael Burgess
Neil Pravin Shah
Francis Y Lee
John S Tokarski
Original Assignee
Bristol Myers Squibb Pharma Co
Univ California
Charles L Sawyers
Michael Burgess
Neil Pravin Shah
Francis Y Lee
John S Tokarski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co, Univ California, Charles L Sawyers, Michael Burgess, Neil Pravin Shah, Francis Y Lee, John S Tokarski filed Critical Bristol Myers Squibb Pharma Co
Priority to US12/092,360 priority Critical patent/US20100029676A1/en
Priority to EP06836906A priority patent/EP1948820A2/en
Publication of WO2007056177A2 publication Critical patent/WO2007056177A2/en
Publication of WO2007056177A3 publication Critical patent/WO2007056177A3/en
Publication of WO2007056177A9 publication Critical patent/WO2007056177A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Abstract

The present invention relates to mutant BCR-ABL kinase proteins, and to diagnostic and therapeutic methods and compositions, for example BMS-354825/dasatinib, useful in the management of disorders, for example cancers, involving cells that express such mutant BCR-ABL kinase proteins.
PCT/US2006/043019 2005-11-04 2006-11-03 T315a and f317i mutations of bcr-abl kinase domain WO2007056177A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/092,360 US20100029676A1 (en) 2005-11-04 2006-11-03 T315a and f317i mutations of bcr-abl kinase domain
EP06836906A EP1948820A2 (en) 2005-11-04 2006-11-03 T315a and f317i mutations of bcr-abl kinase domain

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73338505P 2005-11-04 2005-11-04
US60/733,385 2005-11-04

Publications (3)

Publication Number Publication Date
WO2007056177A2 WO2007056177A2 (en) 2007-05-18
WO2007056177A3 true WO2007056177A3 (en) 2007-07-12
WO2007056177A9 WO2007056177A9 (en) 2008-06-26

Family

ID=37946105

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/043019 WO2007056177A2 (en) 2005-11-04 2006-11-03 T315a and f317i mutations of bcr-abl kinase domain

Country Status (3)

Country Link
US (1) US20100029676A1 (en)
EP (1) EP1948820A2 (en)
WO (1) WO2007056177A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3002009T3 (en) * 2007-06-01 2021-08-02 Wyeth Llc TREATMENT OF IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA, WHICH HAS THE MUTATION 1457T> C IN THE BCRABL GENET, USING THE BOSUTINIB COMPOUND
EP3044324A1 (en) * 2013-09-13 2016-07-20 Life Technologies Corporation Classification and actionability indices for cancer
CA2944043A1 (en) * 2014-03-25 2015-10-01 University Of Utah Research Foundation Peptide inhibitors of bcr-abl oligomerization
CN104372095A (en) * 2014-11-14 2015-02-25 辽宁迈迪生物科技有限公司 Primer, probe and kit for detecting human BCR-ABL gene mutation
CN114736885A (en) * 2022-05-27 2022-07-12 四川大学华西医院 Cell strain carrying BCR-ABL1 gene kinase region double-site mutation and construction method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002102976A2 (en) * 2001-06-14 2002-12-27 The Regents Of The University Of California Mutations in the bcr-abl tyrosine kinase associated with resistance to sti-571

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962225A (en) * 1995-10-27 1999-10-05 Cygene, Inc. Methods and compositions for detection of specific nucleotide sequences
US6180408B1 (en) * 1998-08-21 2001-01-30 Washington University Fluorescence polarization in nucleic acid analysis
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
RU2260592C9 (en) * 1999-04-15 2017-04-07 Бристол-Маерс Сквибб Ко. Cyclic inhibitors of protein-tyrosine kinases
DE10024174A1 (en) * 2000-05-17 2001-11-29 Gsf Forschungszentrum Umwelt Method for selecting inhibitors for enzymes
US20030170851A1 (en) * 2001-10-05 2003-09-11 Christophe Barthe Organic compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002102976A2 (en) * 2001-06-14 2002-12-27 The Regents Of The University Of California Mutations in the bcr-abl tyrosine kinase associated with resistance to sti-571

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BRANFORD SUSAN ET AL: "Major molecular responses to dasatinib (BMS-354825) are observed in imatinib-resistant late stage chronic and advanced CML patients: Impact and fate of imatinib-resistant clones in dasatinib-treated patients.", BLOOD, vol. 106, no. 11, Part 1, November 2005 (2005-11-01), & 47TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ATLANTA, GA, USA; DECEMBER 10 -13, 2005, pages 132A, XP002431108, ISSN: 0006-4971 *
BURGESS MICHAEL R ET AL: "Comparative analysis of two BCR-ABL small molecule inhibitors reveals overlapping but distinct mechanisms of resistance.", BLOOD, vol. 104, no. 11, Part 1, November 2004 (2004-11-01), & 46TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; SAN DIEGO, CA, USA; DECEMBER 04 -07, 2004, pages 160A, XP002414415, ISSN: 0006-4971 *
MANLEY ET AL: "Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - PROTEINS & PROTEOMICS, ELSEVIER, vol. 1754, no. 1-2, 8 September 2005 (2005-09-08), pages 3 - 13, XP005214189, ISSN: 1570-9639 *
O'HARE ET AL: "Targeted CML therapy: controlling drug resistance, seeking cure", CURRENT OPINION IN GENETICS & DEVELOPMENT, CURRENT BIOLOGY LTD, XX, vol. 16, no. 1, February 2006 (2006-02-01), pages 92 - 99, XP005250174, ISSN: 0959-437X *
SAWYERS CHARLES L ET AL: "Hematologic and cytogenetic responses in imatinib-resistant chronic phase chronic myeloid leukemia patients treated with the dual SRC/ABL kinase inhibitor BMS-354825: Results from a phase I dose escalation study.", BLOOD, vol. 104, no. 11, Part 1, November 2004 (2004-11-01), & 46TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; SAN DIEGO, CA, USA; DECEMBER 04 -07, 2004, pages 4A, XP002431106, ISSN: 0006-4971 *
SHAH NEIL P ET AL: "Molecular analysis of dasatinib resistance mechanisms in CML patients identifies novel BCR-ABL mutations predicted to retain sensitivity to imatinib: Rationale for combination tyrosine kinase inhibitor therapy.", BLOOD, vol. 106, no. 11, Part 1, November 2005 (2005-11-01), & 47TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ATLANTA, GA, USA; DECEMBER 10 -13, 2005, pages 318A, XP008077959, ISSN: 0006-4971 *
SHAH NEIL P ET AL: "Overriding imatinib resistance with a novel ABL kinase inhibitor", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 305, no. 5682, 16 July 2004 (2004-07-16), pages 399 - 401, XP002361026, ISSN: 0036-8075 *
SKAGGS BRIAN J ET AL: "Altered oncogenic fitness of imatinib- and dasatinib-resistant BCR-ABL mutants is due to differential intrinsic kinase activity and signaling pathway selection defined by phosphoproteome profiling.", BLOOD, vol. 106, no. 11, Part 1, November 2005 (2005-11-01), & 47TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ATLANTA, GA, USA; DECEMBER 10 -13, 2005, pages 204A, XP008078295, ISSN: 0006-4971 *
TOKARSKI JOHN S ET AL: "The crystal structure of Abl kinase with BMS-354825, a dual SRC/ABL kinase inhibitor.", BLOOD, vol. 104, no. 11, Part 1, November 2004 (2004-11-01), & 46TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; SAN DIEGO, CA, USA; DECEMBER 04 -07, 2004, pages 160A, XP002431104, ISSN: 0006-4971 *
TOKARSKI JOHN S ET AL: "The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants", CANCER RESEARCH, vol. 66, no. 11, June 2006 (2006-06-01), pages 5790 - 5797, XP002431105, ISSN: 0008-5472 *
WALZ ET AL: "Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML)", CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, BOCARATON, FL, US, vol. 57, no. 2, 5 October 2005 (2005-10-05), http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?filters=&orig_db=PubMed&db=PubMed&cmd=Retrieve&list_uids=16213151&dopt=Abstract, pages 145 - 164, XP005282111, ISSN: 1040-8428 *

Also Published As

Publication number Publication date
WO2007056177A2 (en) 2007-05-18
US20100029676A1 (en) 2010-02-04
EP1948820A2 (en) 2008-07-30
WO2007056177A9 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
HK1116349A1 (en) Pyrrolopyrimidines useful as inhibitors of protein kinase
WO2006124748A3 (en) Multicyclic compounds and methods of their use
PH12015500550A1 (en) Anti-notch1 nrr antibodies and methods using same
WO2007056221A3 (en) Aminopyrimidines useful as kinase inhibitors
WO2006081172A3 (en) Compounds and compositions as protein kinase inhibitors
SG151327A1 (en) Deazapurines useful as inhibitors of janus kinases
WO2008115973A3 (en) Aminopyrimidines useful as kinase inhibitors
WO2008039218A3 (en) Inhibitors of bruton's tyrosine kinase
WO2007064797A3 (en) Inhibitors of c-met and uses thereof
WO2007127841A3 (en) Compositions and methods of preparation thereof
WO2005105780A3 (en) Compositions useful as inhibitors of rock and other protein kinases
HK1138572A1 (en) Aminopyrimidines useful as inhibitors of protein kinases
WO2006096489A3 (en) Anti-m-csf antibody compositions having reduced levels of endotoxin
MX2009008787A (en) 2-aminopyrimidine modulators of the histamine h4 receptor.
WO2008137622A3 (en) Aminopyrimidines useful as kinase inhibitors
WO2006131591A3 (en) An entacapone-containing oral dosage form
WO2008076392A3 (en) Compounds useful as protein kinase inhibitors
WO2007022384A3 (en) Pyrazine kinase inhibitors
MX2009010127A (en) N-heterocyclic compounds useful as inhibitors of janus kinases.
UA84929C2 (en) Prodrugs of pyrrolylpyrimidine erk protein kinase inhibitors
WO2007056177A3 (en) T315a and f317i mutations of bcr-abl kinase domain
WO2008112325A3 (en) Treatment of autoimmune disorders
WO2007103468A3 (en) Use of vx-702 for treating rheumatoid arthritis
WO2006128120A3 (en) Novel lapachone compounds and methods of use thereof
WO2007065124A3 (en) Methods of identifying and treating individuals exhibiting complex karyotypes

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006836906

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06836906

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12092360

Country of ref document: US